{"id":"cb-03-01-cream-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"}]},"_chembl":{"chemblId":"CHEMBL2108947","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CB-03-01 selectively inhibits androgen receptor signaling in sebaceous glands and skin, thereby reducing sebum production and the inflammatory cascade that drives acne pathogenesis. By blocking local androgen effects without systemic hormonal suppression, it offers a topical approach to treating acne vulgaris with a potentially favorable safety profile compared to systemic anti-androgens.","oneSentence":"CB-03-01 is an androgen receptor antagonist that blocks the effects of androgens in the skin to reduce sebum production and inflammation associated with acne.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:00.453Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT02608476","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)","status":"COMPLETED","sponsor":"Cassiopea SpA","startDate":"2015-11-16","conditions":"Acne Vulgaris","enrollment":732},{"nctId":"NCT02720627","phase":"PHASE2","title":"An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris","status":"COMPLETED","sponsor":"Cassiopea SpA","startDate":"2016-10-28","conditions":"Acne Vulgaris","enrollment":27},{"nctId":"NCT02608450","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)","status":"COMPLETED","sponsor":"Cassiopea SpA","startDate":"2016-01-21","conditions":"Acne Vulgaris","enrollment":708},{"nctId":"NCT02682264","phase":"PHASE3","title":"An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris","status":"COMPLETED","sponsor":"Cassiopea SpA","startDate":"2016-03-09","conditions":"Acne Vulgaris","enrollment":609},{"nctId":"NCT01631474","phase":"PHASE2","title":"A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Intrepid Therapeutics, Inc.","startDate":"2012-06","conditions":"Acne Vulgaris","enrollment":363}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cortexolone 17α-propionate","clascoterone (USAN, INN)"],"phase":"phase_3","status":"active","brandName":"CB-03-01 cream, 1%","genericName":"CB-03-01 cream, 1%","companyName":"Cassiopea SpA","companyId":"cassiopea-spa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CB-03-01 is an androgen receptor antagonist that blocks the effects of androgens in the skin to reduce sebum production and inflammation associated with acne. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}